A recent narrative review examined disease-modifying therapies for Alzheimer's disease, focusing on approaches that target amyloid-beta and tau proteins. These two proteins are central to the hallmark brain changes seen in Alzheimer's, but the review found that treatments designed to clear or block them have not shown clear clinical benefit in patients.
The review highlights the limitations of single-target approaches, suggesting that Alzheimer's may require combination therapies or strategies that address multiple disease pathways. While the idea of targeting amyloid and tau is scientifically sound, the lack of success in clinical trials indicates that the disease is more complex than initially thought.
Researchers emphasize that these findings do not rule out future success with different drug designs or combinations. However, for now, patients and families should be aware that no disease-modifying therapy has yet proven effective in large-scale studies. The review calls for continued research into novel targets and smarter trial designs.
This summary is based on a narrative review, not a clinical trial, so it does not provide new experimental data. Instead, it synthesizes existing knowledge to guide future research directions.
